SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 3 October 2024Portfolio NewsEnara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
- 2 October 2024Portfolio NewsLoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease
- 24 September 2024Portfolio NewsQuell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma
- 19 September 2024Portfolio NewsPrilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
- 3 September 2024Portfolio NewsPrilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
- 28 August 2024Portfolio NewsMestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300
- 29 July 2024Portfolio NewsBioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide
- 12 July 2024SV NewsUK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce
- 10 July 2024Portfolio NewsQuell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors
- 2 July 2024Portfolio NewsSteven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics
- 2 July 2024Portfolio NewsSitryx announces leadership transition
- 26 June 2024Portfolio NewsTRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases